{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040784","form_type":"8-K","ticker":"FEED","cik":"0001326706","company_name":"ENvue Medical, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.623651+00:00","generated_at":"2026-06-08T03:15:37.368738+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NanoVibronix posts $458K Q3 revenue; CMS reimbursement request not approved","bullets":["Q3 2023 revenue of $458,000; operating loss of $670,000; year-to-date revenue up 22%, operating loss reduced ~20%.","Raised $4.2M net from securities sales; cash & receivables $3.8M, inventory >$3.1M.","UK NHS supply contract and Drug Tariff reimbursement effective Nov 1; UK distributor Peak Medical pursuing opportunities.","Added Mio-Guard as exclusive distributor for Sports segment; VA and Workers Comp channels progressing.","CMS denied full reimbursement again after August 2023 notification; company awaiting response after meeting with CMS leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040784","json":"https://secwatch.observer/filing/0001493152-23-040784.json","markdown":"https://secwatch.observer/filing/0001493152-23-040784.md","text":"https://secwatch.observer/filing/0001493152-23-040784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223040784/0001493152-23-040784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223040784/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:15:37.368738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}